Frontiers in medicine · 2025
Serum levels of interleukin-17, -18, -22, and -25 in patients with bullous pemphigoid before and after treatment.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hong Xinyi, Wang Xiuqin, Cheng Yin, Song Hanqing, Xu Congcong, Wang Peiguang
Аннотация
OBJECTIVE: This study aimed to explore the relationship between serum levels of interleukin-17 (IL-17), interleukin-18 (IL-18), interleukin-22 (IL-22), interleukin-25 (IL-25), anti-BP180 antibodies, anti-BP230 antibodies, and immunoglobulin E (IgE) and the percentage of eosinophils (EOS) in peripheral blood and disease activity and severity in bullous pemphigoid (BP) patients.
METHODS: Blood samples from 61 BP inpatients were collected on the first day of admission and again 1 week after systemic corticosteroid treatment. Additionally, blood specimens were collected from 61 healthy controls. The concentrations of IL-17, IL-18, IL-22, IL-25, IgE, and anti-BP180 or anti-BP230 antibodies were measured using ELISA kits. Various statistical methods were used, including the Wilcoxon test, multifactorial logistic regression, ROC survival curve, and Spearman's correlation analysis.
RESULTS: The mean serum levels of IL-17, IL-18, IL-22, IL-25, and EOS percentage in BP patients were higher than those in healthy controls (all p < 0.001), and all of these levels decreased after treatment (all p < 0.001). There was no statistically significant difference in the titer of anti-BP180 or anti-BP230 antibodies before and after treatment. A binary multivariate logistic regression analysis indicated the statistically significant effect of IL-18, IL-25, or EOS on BP (p < 0.001). Spearman's correlation analysis revealed that the serum levels of IL-17, IL-22, or IL-25 were all strongly correlated with the involved surface area (p < 0.001). In addition, the serum level of IL-17 and the percentage of EOS were associated with the titer of anti-BP180 antibodies (p < 0.05).
CONCLUSION: IL-17, IL-18, IL-22, IL-25, or EOS may be involved in the development of BP, and can be used as biological indicators for monitoring disease severity.
METHODS: Blood samples from 61 BP inpatients were collected on the first day of admission and again 1 week after systemic corticosteroid treatment. Additionally, blood specimens were collected from 61 healthy controls. The concentrations of IL-17, IL-18, IL-22, IL-25, IgE, and anti-BP180 or anti-BP230 antibodies were measured using ELISA kits. Various statistical methods were used, including the Wilcoxon test, multifactorial logistic regression, ROC survival curve, and Spearman's correlation analysis.
RESULTS: The mean serum levels of IL-17, IL-18, IL-22, IL-25, and EOS percentage in BP patients were higher than those in healthy controls (all p < 0.001), and all of these levels decreased after treatment (all p < 0.001). There was no statistically significant difference in the titer of anti-BP180 or anti-BP230 antibodies before and after treatment. A binary multivariate logistic regression analysis indicated the statistically significant effect of IL-18, IL-25, or EOS on BP (p < 0.001). Spearman's correlation analysis revealed that the serum levels of IL-17, IL-22, or IL-25 were all strongly correlated with the involved surface area (p < 0.001). In addition, the serum level of IL-17 and the percentage of EOS were associated with the titer of anti-BP180 antibodies (p < 0.05).
CONCLUSION: IL-17, IL-18, IL-22, IL-25, or EOS may be involved in the development of BP, and can be used as biological indicators for monitoring disease severity.